What does Biospring Partners invest in?
Biospring Partners invests most often at Seed and Series A (90% of the rounds on record), in sectors such as Pharma Services, Biomanufacturing and Clinical Trial Services.

United States · Investor
Filed with the SEC to raise a fund in Apr 2026, closing $5M. Last cheque observed May 2018.
QuietNew fund $5.0M, Apr 2026Private equity
Follow Biospring Partners and see its new cheques in your feed.Start following
10 rounds on record
Mostly Seed and Series A: 90% of its rounds
2 exits from the portfolio
We partner with technology-enabled, EBITDA-positive pharma services businesses driving innovation in manufacturing and clinical trial servicesFrom their own website
Every round we can evidence, newest first10 appearances
1 round
2 rounds
2 rounds
1 round
1 round
3 rounds
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
Named by the firm itself, on a filing, its Form ADV or its company registration4 named
We also hold 15 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
From the firm's own filings with the SEC, which it must file accurately by law
Companies it backed that were later bought or listed2 in all
An exit counts when it came after the firm's first round in the company. From historical deal records.
The investors most often in the same rounds as Biospring Partners. A count of rooms they were both in, not a relationship either has claimed.
The latest companies Biospring Partners put money into.
Biospring Partners invests most often at Seed and Series A (90% of the rounds on record), in sectors such as Pharma Services, Biomanufacturing and Clinical Trial Services.
10 investments on record, 0 of them in the last 12 months. The most recent was in May 2018.
Its most recent investments on record: Sentenai (Seed, May 2018).
The median round it joins is $2.0M.
Rarely, if at all: none of its 10 investments on record names it as the lead.
Most of the companies it backs are in the United States (90%) and Canada (10%).
No investments in the last 12 months; the latest was in May 2018.
Most often Roy Rodenstein (3 rounds together), Apricot Capital (2 rounds together) and David Chang (2 rounds together).
Find the investors who back rounds like yours, and keep every conversation on one fundraising board.
Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it